Skip to main content
Log in

Midazolam-induced rapid changes in licking behaviour: evidence for involvement of endogenous opioid peptides

  • ORIGINAL INVESTIGATION
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The role of endogenous opioid peptides in the effects of midazolam on ingestive behaviour was investigated using a detailed analysis of licking behaviour in the rat. Midazolam (1.8 mg/kg IP) was administered in combination with either flumazenil (10 and 20 mg/kg IP) or naloxone (0.1 and 0.3 mg/kg IP). The effect on licking patterns during 60-s exposures to a range of concentrations of a fat emulsion (Intralipid) was then recorded. Midazolam significantly increased the total number of licks for Intralipid by increasing the mean bout duration. This effect is consistent with the proposal that benzodiazepines enhance palatability. Flumazenil and naloxone were ineffective when administered alone, but both drugs blocked the effect of midazolam on total number of licks by selectively attenuating mean bout duration. Midazolam also produced a significant decrease in the intrabout lick rate, probably due to the muscle relaxant effects of this drug. This decrease in the intrabout lick rate was reversed by pretreatment with flumazenil but not by naloxone. The results suggest that endogenous opioids may be important for the palatability effects of midazolam, but may not be involved in the muscle relaxant effects of this drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 20 August 1996/Final version: 16 January 1997

Rights and permissions

Reprints and permissions

About this article

Cite this article

Higgs, S., Cooper, S. Midazolam-induced rapid changes in licking behaviour: evidence for involvement of endogenous opioid peptides. Psychopharmacology 131, 278–286 (1997). https://doi.org/10.1007/s002130050294

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002130050294

Navigation